The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Seed VC | Alive

About DyNAbind

DyNAbind offers partnerships and solutions for drug discovery with Dynamic DNA-Encoded Library (D-DEL) technologies. The company introduces proprietary developments in library design, selection and validation, all of which lead to a faster path to high-quality, relevant starting points for medicinal chemistry – and the only DEL platform on the market fully designed to integrate with a fragment-based discovery methodology.

DyNAbind Headquarter Location

Tatzberg 47

Dresden, 01307,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing DyNAbind

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DyNAbind is included in 1 Expert Collection, including Omics.



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Latest DyNAbind News

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel...

Sep 17, 2019

Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBodyTM-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms of the agreement, Confo Therapeutics will gain exclusive, worldwide rights to any drug candidates arising from the collaboration and will be responsible for their development, manufacturing and commercialization. Commenting on the deal, Dr Christel Menet, Confo Therapeutics’ CSO, said: “This collaboration will leverage the combination of two cutting-edge technologies to expand our universe of hits on a GPCR previously thought to be intractable. We look forward to working with the DyNAbind team on this exciting project.” Dr Michael Thompson, co-founder and CEO of DyNAbind added: “GPCRs are high-potential targets for drug discovery, but have been traditionally difficult to work with. Confo Therapeutics’ technology has proven itself to be a powerful tool for the stabilization of GPCRs in a particular conformation. Partnered with the increased signal-to-noise ratios seen with our Dynamic Library technology, we are in a strong position to identify drug candidates against this specific target. ” For more information please contact: Confo Therapeutics For English-speaking and International Media: Instinctif Partners for Confo Therapeutics Dr Christelle Kerouedan, Sue Charles | + 44 (0)20 7457 2020 | For Belgian Media:

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.